Publications
487
Citations
14,374
Est. group size
~96
Recurring co-author estimate
Active years
53
Publishing since 1974
Robert A. Baiocchi studies lymphoma (cancers of the immune system's lymph cells) with a particular focus on Epstein-Barr virus (EBV)-associated lymphomas and lymphoproliferative disease after transplants, as well as treatment resistance mechanisms in B-cell malignancies. His work spans laboratory studies of cancer biology (such as gene regulation and drug resistance pathways), clinical trials of new therapies, and mouse models of lymphoma, often in collaboration with a large multi-author research network. Prospective students would likely engage with a mix of basic cancer biology, translational research, and clinical trial data analysis.
Publication output has grown substantially over the last decade, rising from roughly a dozen papers per year in 2017 to 40-70+ per year in 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome
Blood Advances · 2026
- Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study
medRxiv · 2026
- BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance
Nature Communications · 2026
- Malignancy-Induced Functional Tricuspid Obstruction Complicated by Cardiopulmonary Collapse Treated Using Combination VA-ECMO and AngioVac
JACC Case Reports · 2025
- Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma
Journal of the National Comprehensive Cancer Network · 2025
- EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap
Journal of Medical Virology · 2025
- Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Journal of Hematology & Oncology · 2025
- Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
Transplantation and Cellular Therapy · 2025
- Exploring PRMT5 Inhibition As a Therapeutic Strategy in Primary and Secondary Hemophagocytic Lymphohistiocytosis
Transplantation and Cellular Therapy · 2025
- Abstract 3242: DNA methylation profiling of Epstein-Barr virus (EBV) in lymphoproliferative disease reveals diagnostic and therapeutic applications
Cancer Research · 2025
- 124 | Updated Results: Ph 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with EBV+ PTLD after Rituximab+/‐ Chemotherapy Failure
Hematological Oncology · 2025
- Abstract P39: Genome-Wide Analysis of Epstein-Barr Virus (EBV) in Lymphoma Patients from Ethiopia
Cancer Research · 2025
- Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
UNC Libraries · 2025
- The Novel Immunocompetent Eµ-SOX11CCND1 Mouse Model Phenotypically and Molecularly Resembles Human Mantle Cell Lymphoma
Clinical Cancer Research · 2025
- CT-1086: Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy
Clinical Lymphoma Myeloma & Leukemia · 2025
- Blood×72
- Cancer Research×13
- Blood Advances×12
- Hematological Oncology×11
- Clinical Lymphoma Myeloma & Leukemia×7
- Carl Quinion
Medicine · The Ohio State University
- David A. Bond
Medicine · The Ohio State University
- Kaitlin Annunzio
Medicine · The Ohio State University
- Timothy Voorhees
Medicine · The Ohio State University
- Beth Christian
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile